WEBULL
WebtradeDownload

Is Carl Zeiss Meditec (XTRA:AFX) Undervalued Following Its Investor Conference Appearance?

Simply Wall St · 20h ago

Carl Zeiss Meditec (XTRA:AFX) is back in the spotlight as CFO Justus Felix Wehmer prepares to address investors at the Berenberg and Goldman Sachs German Corporate Conference on 23 September in Munich.

Recent moves have been choppy for Carl Zeiss Meditec, with a 2.80% 1 day share price return and 8.68% 7 day share price return, set against a year to date share price decline of 20.39% and a 1 year total shareholder return fall of 24.51%.

Compare Carl Zeiss Meditec with a hand picked group of potential mispriced opportunities by scanning the 179 high quality undervalued stocks that share solid fundamentals and valuation gaps.

After a long slide and a recent bounce, Carl Zeiss Meditec now trades at a steep intrinsic discount while sitting below analyst targets. Is the market being cautious for good reason, or overly harsh on this business?

Most Popular Narrative: 16% Overvalued

Carl Zeiss Meditec closed at €31.54, while the most followed valuation story points to a fair value of €27.15, which implies the market price sits above that narrative estimate and bakes in richer expectations than the underlying model.

The recent approval of the VISUMAX 800 in China, earlier than expected, positions Carl Zeiss Meditec AG for potential revenue growth. The launch is expected to boost higher ASP (Average Selling Price) for both devices and treatment packs, enhancing future revenue streams.

See why 33 investors see Carl Zeiss Meditec as 16% overvalued.

Result: Fair Value of €27.15 (OVERVALUED)

Still, Carl Zeiss Meditec faces pressure from weaker conditions in China and a sharp 57.1% drop in net income that could unsettle the bullish narrative.

Find out about the key risks to this Carl Zeiss Meditec narrative.

Another View On Carl Zeiss Meditec's Value

Analysts see Carl Zeiss Meditec as 16% above their €27.15 fair value estimate, yet our DCF model points the other way and flags deep undervaluation. On this cash flow view, the stock price of €31.54 sits far below an estimated €79.17. Which story do you trust more: sentiment or spreadsheets?

Look into how the SWS DCF model arrives at its fair value.

AFX Discounted Cash Flow as at Sep 2026
AFX Discounted Cash Flow as at Sep 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Carl Zeiss Meditec for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 179 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment on Carl Zeiss Meditec is clearly split, which is exactly why checking the underlying data yourself matters. Act before the next narrative hardens around the stock and use the 2 key rewards and 1 important warning sign.

Looking for more Carl Zeiss Meditec style investment ideas?

If the split views on Carl Zeiss Meditec have you thinking bigger, broaden your watchlist now with fresh ideas before the next move leaves you catching up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.